 |
|
|
| |
Twelve- or 16-Week Treatment With Daclatasvir Combined With Peginterferon Alfa and Ribavirin
for Hepatitis C Virus Genotype 2 or 3 Infection: COMMAND GT 2/3 Study
|
| |
| |
Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
Dore GJ,1 Lawitz E,2 Hezode C,3 Shafran S,4 Ramji A,5 Tatum H,6 Taliani G,7 Tran A,8 Brunetto M,9 Zaltron S,10 Strasser S,11 Weis N,12 Ghesquiere W,13 Lee S,14 Larrey D,15 Pol S,16
Harley H,17 George J,18 Fung S,19 de Ledinghen V,20 Hagens P,21 Cohen D,22 Noviello S,23 Hughes EA,23 Cooney E22
1Kirby Institute, University of New South Wales and St Vincent's Hospital, Sydney, Australia; 2Alamo Medical Research, San Antonio, TX; 3Hôpital Henri Mondor, Creteil, France; 4University of Alberta, Edmonton, AB, Canada; 5Gastrointestinal Research Institute, Vancouver, BC, Canada; 6Options Health Research, Tulsa, OK; 7Azienda Ospedaliera Universitaria, Rome, Italy; 8Hôpital De L'Archet 2, Nice, France; 9University Hospital, Pisa, Italy; 10Azienda Ospedaliera Spedali Civili, Brescia, Italy; 11Royal Prince Alfred Hospital, Sydney, Australia; 12Copenhagen University Hospital, Hvidovre, Denmark; 13Vancouver Island Health Authority, Victoria, BC, Canada; 14Heritage Medical Research Clinic, University of Calgary, Calgary, AB, Canada; 15Hôpital Saint Eloi, Montpellier, France; 16Universite Paris Descartes, Hôpital Cochin, Paris, France; 17Royal Adelaide Hospital, Adelaide, Australia; 18Westmead Hospital and Westmead Millennium Institute, University of Sydney, Sydney, Australia; 19Toronto General Hospital, Toronto, ON, Canada; 20Hôpital Haut-Levêque, Pessac, France; 21Bristol-Myers Squibb Research and Development, Braine-l'Alleud , Belgium; 22Bristol-Myers Squibb Research and Development, Wallingford, CT; 23Bristol-Myers Squibb Research and Development, Princeton, NJ
|
| |
|
|
|
|
|
